Provectus Biopharmaceuticals Stock Price, News & Analysis (OTCMKTS:PVCT)

$0.04 0.00 (0.00 %)
(As of 11/20/2017 04:14 AM ET)
Previous Close$0.04
Today's Range$0.04 - $0.04
52-Week Range$0.01 - $0.07
Volume97,850 shs
Average Volume597,513 shs
Market Capitalization$15.2 million
P/E RatioN/A
Dividend YieldN/A

About Provectus Biopharmaceuticals (OTCMKTS:PVCT)

Provectus Biopharmaceuticals logoProvectus Biopharmaceuticals, Inc. is a development-stage biopharmaceutical company. The Company is engaged in developing pharmaceuticals for oncology and dermatology indications. The Company is focused on developing its prescription drug candidates, PV-10 and PH-10. It is developing PV-10 for treatment of several life threatening cancers, including metastatic melanoma, liver cancer and breast cancer. It is developing PH-10 to provide minimally invasive treatment of chronic severe skin afflictions, such as psoriasis and atopic dermatitis, a type of eczema. In addition to clinical trials, patients enrolled in the expanded access or compassionate use program for PV-10 are also receiving PV-10 treatments for cutaneous and subcutaneous cancer indications. The Company also focuses on over-the-counter (OTC) products and various other non-core technologies. PV-10 is a sterile injectable form of rose bengal disodium (Rose Bengal), for direct injection into tumors.

Industry, Sector and Symbol:
  • Industry: Drug Manufacturers - Major
  • Sub-Industry: N/A
  • Sector: Medical
  • Symbol: OTCMKTS:PVCT
  • Previous Symbol: NYSEMKT:PVCT
  • CUSIP: N/A
  • Web:
  • Debt-to-Equity Ratio: -0.97%
  • Current Ratio: 0.13%
  • Quick Ratio: 0.13%
Sales & Book Value:
  • Annual Sales: N/A
  • Price / Sales: N/A
  • Book Value: $0.01 per share
  • Price / Book: 4.10
  • Trailing EPS: ($0.08)
  • Net Income: ($24,420,000.00)
  • Return on Equity: -2,045.29%
  • Return on Assets: -334.46%
  • Employees: 2
  • Outstanding Shares: 370,740,000

Frequently Asked Questions for Provectus Biopharmaceuticals (OTCMKTS:PVCT)

What is Provectus Biopharmaceuticals' stock symbol?

Provectus Biopharmaceuticals trades on the OTCMKTS under the ticker symbol "PVCT."

Who are some of Provectus Biopharmaceuticals' key competitors?

Who are Provectus Biopharmaceuticals' key executives?

Provectus Biopharmaceuticals' management team includes the folowing people:

  • Dominic Rodrigues, Chairman of the Board
  • Timothy C. Scott Ph.D., President (Age 51)
  • John R. Glass CPA, Interim Chief Financial Officer (Age 72)
  • Eric A. Wachter Ph.D., Chief Technology Officer, Director (Age 52)
  • Bruce Horowitz, Director
  • Jan E Koe, Independent Director (Age 65)

How do I buy Provectus Biopharmaceuticals stock?

Shares of Provectus Biopharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Provectus Biopharmaceuticals' stock price today?

One share of Provectus Biopharmaceuticals stock can currently be purchased for approximately $0.04.

How big of a company is Provectus Biopharmaceuticals?

Provectus Biopharmaceuticals has a market capitalization of $15.2 million. The company earns ($24,420,000.00) in net income (profit) each year or ($0.08) on an earnings per share basis. Provectus Biopharmaceuticals employs 2 workers across the globe.

How can I contact Provectus Biopharmaceuticals?

Provectus Biopharmaceuticals' mailing address is 10025 INVESTMENT DRIVE SUITE 250, KNOXVILLE TN, 37932. The company can be reached via phone at 865-769-4011 or via email at [email protected]

MarketBeat Community Rating for Provectus Biopharmaceuticals (OTCMKTS PVCT)

Community Ranking:  5.0 out of 5 (star star star star star)
Outperform Votes:  1 (Vote Outperform)
Underperform Votes:  0 (Vote Underperform)
Total Votes:  1
MarketBeat's community ratings are surveys of what our community members think about Provectus Biopharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for Provectus Biopharmaceuticals (OTCMKTS:PVCT)

  (How are Consensus Ratings Calculated?)
Ratings Breakdown: 0 Sell Ratings, 0 Hold Ratings, 0 Buy Ratings, 0 Strong Buy RatingsNo ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Analysts' Consensus Price Target: N/A

Consensus Price Target History for Provectus Biopharmaceuticals (OTCMKTS:PVCT)

Price Target History for Provectus Biopharmaceuticals (OTCMKTS:PVCT)

Analysts' Ratings History for Provectus Biopharmaceuticals (OTCMKTS:PVCT)

No equities research coverage for this company has been tracked by


Earnings History and Estimates Chart for Provectus Biopharmaceuticals (OTCMKTS:PVCT)

Earnings by Quarter for Provectus Biopharmaceuticals (OTCMKTS:PVCT)

Earnings History by Quarter for Provectus Biopharmaceuticals (OTCMKTS PVCT)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/6/2015Q215($0.02)$1.08 millionViewN/AView Earnings Details
5/7/2015Q115($0.02)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Provectus Biopharmaceuticals (OTCMKTS:PVCT)

No earnings estimates for this company have been tracked by


Dividend History for Provectus Biopharmaceuticals (OTCMKTS:PVCT)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for Provectus Biopharmaceuticals (OTCMKTS PVCT)
No insider trades for this company have been tracked by


Latest Headlines for Provectus Biopharmaceuticals (OTCMKTS PVCT)

No headlines for this company have been tracked by

Social Media



Provectus Biopharmaceuticals (OTCMKTS PVCT) Chart for Monday, November, 20, 2017
Loading chart…

This page was last updated on 11/20/2017 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.